Advertisement

Topics

GSK reports long-term benefits with Benlysta in lupus study

05:54 EDT 21 Jun 2017 | SmartBrief

Data from a midstage trial of GlaxoSmithKline's Benlysta, or belimumab, showed an overall response of 65.1% at year 10 among  -More

Original Article: GSK reports long-term benefits with Benlysta in lupus study

NEXT ARTICLE

More From BioPortfolio on "GSK reports long-term benefits with Benlysta in lupus study"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...